TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Enteral Feeding in Discharged Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients able to give written informed consent,~* Have had a feeding jejunostomy placed at surgery,~* Competent (or their carer) to set up and use the jejunostomy feeding apparatus themselves.~Exclusion Criteria:~* Participating in another interventional trial,~* Age \<18,~* Pre-operative BMI \> 35,~* Pre-operative BMI \<18,~* Oral intake at hospital discharge of \> 90% of requirements,~* It is felt that they or their carers would not to cope with home tube feeding Patients unable to give written informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Jejunal feeding (Type: ACTIVE_COMPARATOR): Nutritional supplementation via their jejunostomies for six weeks post hospital discharge, with continued assessment for a further 18 weeks.
- No jejunal feeding (Type: NO_INTERVENTION): No jejunal feeding of patients for six weeks following hospital discharge, with continued assessment for a further 18 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Same-Day Discharge After Coronary Percutaneous Transluminal Coronary Angioplasty (PTCA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Scheduled for catheterization/coronary angiography~2. Undergoing diagnostic coronary angiography to define the coronary anatomy with the intent for revascularization (ad-hoc PCI) or planned PCI to define the coronary anatomy with the intent for revascularization due to one of the following:~   1. exertional or rest chest pain (or angina equivalent)~  2. abnormal Exercise Stress Test~  3. abnormal nuclear tests~  4. abnormal pharmacologic or stress echocardiogram, or pharmacologic MRI~  5. abnormal EKGs~  6. abnormal Calcium scores~  7. abnormal coronary CT angiogram~3. Ability and willingness to consent and Authorization for use of PHI~Exclusion Criteria:~1. ACS (STEMI, UA/NSTEMI)~2. Positive Troponin I per local laboratory standards~3. Known EF\<30%~4. GFR\<50% (calculation using the IDMS-Traceable MDRD study equation~5. Dye Allergy that unable to be safely premedicated~6. Known current or history of bleeding diathesis~7. Current or anticipated treatment with warfarin, oral factor Xa inhibitor, oral direct thrombin inhibitor, LMWH, or TNK~8. Known platelet count \<100,000/mm³ or known INR \>1.5 at time of enrollment~9. Hgb \<10 g/dL and/or Hct \< 30%~10. Residence \>60 minutes from the hospital~11. Reliable caregiver not available for home post PCI recovery~12. Participation in another study that would require hospital procedures or test post PCI prior to discharge~13. Inability or unwillingness to consent for study, follow up procedures and Authorization for use of PHI~14. Physician clinical determination participant is not suitable for study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Same-day discharge (Type: EXPERIMENTAL): Same-day discharge following PCI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Amiodarone Given Before Lung Surgery to Prevent Atrial Fibrillation After Lung Resection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Resectable lung nodule or mass~Exclusion Criteria:~* Allergy to amiodarone~* Currently taking amiodarone~* Documented atrial fibrillation within past 12 months~* Known pulmonary fibrosis~* Known hepatic dysfunction~* Thyroid disease~* 2nd or 3rd degree heart block~* Severe SA node disease~* Bradycardia-induced syncope~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 - Amiodarone (Type: EXPERIMENTAL): Perioperative amiodarone
- 2 - Control (Type: ACTIVE_COMPARATOR): Control arm, standard care with no perioperative amiodarone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Psychometric Testing and Cue Utilization During Cued Visual Search

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Normal or corrected-to-normal visual acuity, normal color vision~Exclusion Criteria:~* age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Attentional Tests- Miyake and others (Type: EXPERIMENTAL): All participants will complete a series of behavioral tasks, including cued visual search with positive, negative, and neutral cues, Miyake executive attention tasks, and a visual working memory task. Single Arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: CMR-Lupus Comprehensive Approach by Cardiovascular Magnetic Resonance Tomography

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of SLE, as defined by the American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus~Exclusion Criteria:~* age under 18 years~* known coronary artery disease~* impaired renal function with an estimated glomerular filtration rate less than 30 ml/min, estimated by the Modification of Diet in Renal Disease Study Group (MDRD) formula (45)~* devices as pacemakers, implantable cardioverter-defibrillators, insulin pumps and others~* metallic foreign bodies in the eyes, ferromagnetic implants labeled MR unsafe~* allergy against CMR contrast media or adenosine~* presence of chronic atrial fibrillation, 2nd or 3rd degree Atrioventricular (AV)-block, trifascicular block, asthma and severe chronic obstructive pulmonary disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Sleeve Gastrectomy Technique With a Nissen Fundoplication Added to the Conventional Sleeve Gastrectomy Technique in Morbidly Obese Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent form~* Subjects must be able to attend all scheduled visits and to comply with all trial procedures~* Subjects must be covered by public health insurance~* Contraception efficacy~* Subjects eligible for sleeve gastrectomy after multidisciplinary evaluation according to HAS 2009 criteria: BMI ≥ 40 kg / m² with failure of the dietary treatment for at least 1 year, or a BMI ≥ 35kg / m² with at least one co-morbidity that could be improved after surgery (hypertension, obstructive sleep apnea hypopnea syndrome (OSAHS) and other severe respiratory disorders, severe metabolic disorders (especially type 2 diabetes), debilitating musculoskeletal diseases, non-alcoholic steato-hepatitis (NASH))~Exclusion Criteria:~* Subject unable to read or/and write~* Planned longer stay outside the region that prevents compliance with the visit plan~* Current pregnancy~* Previous bariatric surgery (ring, vertical banded gastroplasty, sleeve gastrectomy or Gastric Bypass).~* BMI \> 50 kg / m² for women and \> 45kg / m² for men (dissecting the hiatus region can be a technical challenge in these cases).~* Barrett oesophagus and esophagitis stage III and IV.~* Funditis~* Long-term NSAIDs and/or corticosteroid therapy~* No affiliation at the French social security scheme.~* Major protected by law.~* Deprivation of liberty by judicial or administrative decision.~* Participation to another clinical research program.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- N SLEEVE (Type: EXPERIMENTAL): Monocentric, randomized, single-blind controlled trial, with 2 parallel arms (experimental technique versus surgical reference technique).
- SLEEVE (Type: OTHER): The conventional sleeve gastrectomy technique consists of reducing the gastric capacity by removing 2/3 of the stomach by a vertical transection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Single Embryo Transfer Versus Double Embryo Transfer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:G~* Good prognosis IVF patients~Exclusion Criteria:~* Bad prognosis IVF patients

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 37 Years
- Healthy Volunteers: f

Study Arms:
- SET on day 3 (Type: EXPERIMENTAL): Single embryo transfer on day 3 of embryo development
- DET on day 3 (Type: EXPERIMENTAL): Double embryo transfer on day 3 of embryo development
- SET on day 5 (Type: EXPERIMENTAL): Single embryo transfer on day 5 of embryo development
- DET on day 5 (Type: EXPERIMENTAL): Double embryo transfer on day 5 of embryo development

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Mindfulness Training for Senior Leaders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Individuals who are between 18 and 65 years of age.~2. Individuals who are fluent English speakers.~3. Individuals who are active-duty service members~4. Individuals who are willing and able to consent to participate in the study.~5. Individuals who participated in the courses provided by the Army War College (AWC).~Exclusion Criteria:~1. Individuals who have been hospitalized for psychological/mental health issues within the last month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Group A (MT group) (Type: EXPERIMENTAL): Participants will receive 4 weeks of mindfulness training during the first training interval between the first (T1) and second (T2) assessment sessions.
- Group B (Wait-list group) (Type: ACTIVE_COMPARATOR): Participants will not receive 4 weeks of mindfulness training during the first training interval; they will receive 4 weeks of mindfulness training during the second training interval between the second (T2) and third (T3) assessment sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial (INSTANT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female able to understand and sign a witnessed informed consent,~* age ≥ 18 years~* patients with stable (Canadian Cardiovascular Society I-IV) or unstable angina pectoris (but with the most recent anginal episode occurring \>48 hours before the procedure \[provided that the most recent CK-MB mass levels are within the limits of normal\]) or documented silent ischemia~* stable hemodynamic conditions (systolic blood pressure\>100, heart rate\>40 and \<100)~* no clinical and ECG changes suggestive of ongoing acute or recent (\<48 hours) myocardial infarction.~Exclusion Criteria:~* female sex with childbearing potential~* age \<18 years~* ongoing or recent episode (\<48 hours) of unstable coronary artery disease (including both ST-elevation and non-ST-elevation acute coronary syndromes) without normalization of CK-MB mass levels~* administration of any GP IIb/IIIa inhibitors during the previous 2 weeks,~* serum creatinine \>2.5 mg/dl or \> 350 micromols/l~* ongoing serious bleeding or bleeding diathesis~* previous stroke in the last 6 months~* major surgery within the previous 6 weeks~* platelet count \<100,000 per mm3~* ejection Fraction below 30%~* known hypersensitivity or contraindication to aspirin, heparin, clopidogrel or sensitivity to contrast which cannot be adequately pre-medicated~* hemodynamic instability (systolic blood pressure\<100 mm Hg; heart rate\<40 bpm or \>100 bpm; complex ventricular arrhythmias; atrioventricular block) requiring balloon counterpulsation or inotropic support~* simultaneous participation in another device or drug study (patient must have completed the follow-up phase of any previous study at least 30 days prior to enrollment in this study)~* positive clinical history for intracranial neoplasia, arterio-venous malformation, aneurysm~* INR ≥ 2.0 or prothrombin time 1.2 times upper limit of normality~* clinically manifested reduced liver function~* programmed surgery within one month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eptifibatide (Type: EXPERIMENTAL): Intravenous eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure).
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: COVID-19 Wellness Survey

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~-~Exclusion Criteria:~* Under the age of 18 and anyone who does not currently reside in the United States

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- COVID-19 Survey Group (Type: None): Group of individuals participating in the survey via self-selection. There is not intervention being administered. The group is simply answering questions on their health behaviors before COVID-19 and their health behaviors in the past 7-30 days, during the COVID-19 outbreak in the United States.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: DermaClose DUKE Fasciotomy and Wound Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is at least 18 years of age at the time of consent.~* Patient with a full thickness acute wound(s) of the skin:~  1. On either the upper or lower extremity (including four-compartment leg fasciotomy), in whom DermaClose and/or DermaClose XL is applied during surgery, OR~ 2. Undergoing a four-compartment leg fasciotomy requiring conventional wound dressing.~* Patient has signed a written informed consent form (ICF) per 21 Code of Federal Regulations (CFR) Part 50.55(e).~Exclusion Criteria:~* Patient in whom the product was used off-label (except for patients who have the device on for longer than 14 days)~* Patient with wound(s) that exhibit any of the following:~  * Ischemic tissue,~ * Infected tissue,~ * Acute burned tissue,~ * Fragile tissue at the edges of the wound(s).~* Patient, who in surgeon's opinion, does not fit the criteria for this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Wound on either the upper or lower extremity with DermaClose and/or DermaClose XL (Type: None): Non-fasciotomy
- Wound undergoing fasciotomy with DermaClose and/or DermaClose XL (Type: None): None
- Wound undergoing fasciotomy with conventional wound dressings (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CMAC® Versus Airtraq® and Macintosh Laryngoscope in Difficult Tracheal Intubation.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ASA 1-3 patients undergoing surgical procedures requiring orotracheal intubation.~* Written informed Consent~* No relevant drug allergies~* Patients with 2 or more of the following predictors of difficult intubation:~  * Mallampatti II - IV~ * Thyromental distance \< 6cm~ * Mouth opening \< 3.5 cm~ * Cervical spine disease~ * Anteriorly protruding incisors~ * Presence of Caps or Crowns~Exclusion Criteria:~* Patients with history of or risk factors for gastric regurgitation~* Patients unable to consent for the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- macintosh (Type: ACTIVE_COMPARATOR): None
- C-MAC (Type: ACTIVE_COMPARATOR): None
- Airtraq (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Exercise Intervention - and Impact on Hospitalization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
inclusion= waitlisted for liver transplant with poor 6MWT~Exclusion criteria include: age \< 18 years, recent hospitalization (within 14 days) due to decompensation, variceal bleeding in the previous 1 month, large esophageal varices without primary prophylaxis, active excessive alcohol intake (in the previous 3 months), current overt uncontrolled hepatic encephalopathy, hepatopulmonary syndrome with uncontrolled hypoxia, portopulmonary hypertension, inability to perform exercise, or marked symptomatic comorbidities (cardiac, pulmonary, renal). multiorgan transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- home exercise (Type: ACTIVE_COMPARATOR): participate in home exercise program
- standard care (Type: PLACEBO_COMPARATOR): encouraged to join physical therapy and walking goals

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Undergoing robotic assisted prostatectomy or robotic assisted partial nephrectomy at University of Missouri Hospital for prostate cancer or kidney mass~* Age ≥ 18 years~* ASA I-III~Exclusion Criteria:~* Inability to obtain written informed consent~* Allergy to lidocaine or other amide local anesthetics~* Atrioventricular conduction blocks~* CV instability and concomitant use of alpha agonists or beta blockers~* Recent myocardial infarction (≤ 6 months ago)~* Cardiac arrhythmia disorders~* Stokes-Adams syndrome~* Wolff-Parkinson-White syndrome~* Seizure disorders~* Liver failure or hepatic dysfunction~* Significant renal disease with a serum creatinine ≥ 2 mg/dl~* A family history of malignant hyperthermia~* Current use of opioids or documented history of opioid abuse~* Typically, have less than 3 bowel movement per week~* Combined surgical cases that include robotic prostatectomy or robotic partial nephrectomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: ACTIVE_COMPARATOR): Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution
- Control group (Type: PLACEBO_COMPARATOR): 0.9% Sodium Chloride Injection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues